[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR009627A1 - DERIVATIVES OF N- (IMIDAZOLYLBUTYL) BENZENOSULFONAMIDE ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS - Google Patents

DERIVATIVES OF N- (IMIDAZOLYLBUTYL) BENZENOSULFONAMIDE ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS

Info

Publication number
AR009627A1
AR009627A1 ARP970105455A ARP970105455A AR009627A1 AR 009627 A1 AR009627 A1 AR 009627A1 AR P970105455 A ARP970105455 A AR P970105455A AR P970105455 A ARP970105455 A AR P970105455A AR 009627 A1 AR009627 A1 AR 009627A1
Authority
AR
Argentina
Prior art keywords
alkyl
application
benzenosulfonamide
imidazolylbutyl
therapeutics
Prior art date
Application number
ARP970105455A
Other languages
Spanish (es)
Original Assignee
Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthelabo filed Critical Synthelabo
Publication of AR009627A1 publication Critical patent/AR009627A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/68Halogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos de formula (I): en donde, entre otros significados R1 y R1 representan hidrogeno, halogeno o (C1-C4)alquilo; R2 representa un grupopiperidin-1-ilo, 1,2,3,6-tetrahidropidin-1-ilo eventualmente substituidos, hexahidro-1H-azepin-1-ilo, heptahidroazocin-1-ilo, octahidro-1H-azonin-1-ilo,(1) donde: (A-B = ONR, m = 1 a 2 y p = 1 a 2); (2) donde: (Q = carbono o nitrogeno, D = (C1-C4)alquilo o -CH2CH3, y r = 1 a 3), R3 representa (C1-C5)alquilo, -COR5 [siendo R5 (C1-C4)alquilo,-(CH-2)nOCH3, -CH2O(C2H4O)nCH3, -(CH2)nCF3, -(CH-2)nOH (n igual 1 a 4)], -SO2R6, -CONHR6, -SO2N(R6)2 (siendo R6(C1-C4)alquilo; R4 representa hidrogeno o halogeno y A representa fenilo o heterociclo eventualmente substituidos o ciclo(C5-C8)alquilo. Aplicacion enterapéutica: propiedades antitromboticas.Compounds of formula (I): wherein, among other meanings R1 and R1 represent hydrogen, halogen or (C1-C4) alkyl; R2 represents a group piperidin-1-yl, optionally substituted 1,2,3,6-tetrahydropidin-1-yl, hexahydro-1H-azepin-1-yl, heptahydroazocin-1-yl, octahydro-1H-azonin-1-yl , (1) where: (AB = ONR, m = 1 to 2 and p = 1 to 2); (2) where: (Q = carbon or nitrogen, D = (C1-C4) alkyl or -CH2CH3, and r = 1 to 3), R3 represents (C1-C5) alkyl, -COR5 [where R5 (C1-C4) alkyl, - (CH-2) nOCH3, -CH2O (C2H4O) nCH3, - (CH2) nCF3, - (CH-2) nOH (n equal 1 to 4)], -SO2R6, -CONHR6, -SO2N (R6) 2 (where R6 (C1-C4) is alkyl; R4 represents hydrogen or halogen and A represents optionally substituted phenyl or heterocycle or (C5-C8) alkyl. Enteratherapeutic application: antithrombotic properties.

ARP970105455A 1996-11-22 1997-11-21 DERIVATIVES OF N- (IMIDAZOLYLBUTYL) BENZENOSULFONAMIDE ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS AR009627A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9614309A FR2756285B1 (en) 1996-11-22 1996-11-22 N- (IMIDAZOLYLBUTYL) BENZENESULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION

Publications (1)

Publication Number Publication Date
AR009627A1 true AR009627A1 (en) 2000-04-26

Family

ID=9497920

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970105455A AR009627A1 (en) 1996-11-22 1997-11-21 DERIVATIVES OF N- (IMIDAZOLYLBUTYL) BENZENOSULFONAMIDE ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS

Country Status (20)

Country Link
EP (1) EP0946517A1 (en)
JP (1) JP2001504128A (en)
KR (1) KR20000069063A (en)
CN (1) CN1238765A (en)
AR (1) AR009627A1 (en)
AU (1) AU5226498A (en)
BG (1) BG103414A (en)
BR (1) BR9713291A (en)
CA (1) CA2270478A1 (en)
CO (1) CO4910158A1 (en)
CZ (1) CZ178299A3 (en)
EE (1) EE9900201A (en)
FR (1) FR2756285B1 (en)
HU (1) HUP9904599A2 (en)
IL (1) IL129546A0 (en)
NO (1) NO992436L (en)
SK (1) SK66799A3 (en)
TR (1) TR199901143T2 (en)
WO (1) WO1998022443A1 (en)
ZA (1) ZA9710515B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2783521B1 (en) * 1998-09-18 2002-04-26 Synthelabo N- (ARGINYL) BENZENESULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
FR2806722B1 (en) * 2000-03-23 2002-05-17 Sanofi Synthelabo N- (HETEROCYCLYLBUTYL) BENZENE- OR PYRIDINE SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
ES2799309T3 (en) 2014-09-29 2020-12-16 Cellix Bio Private Ltd Compounds and compositions for the treatment of multiple sclerosis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2689130B1 (en) * 1992-03-30 1994-05-27 Synthelabo DERIVATIVES OF 1- [2 (ARYLSULFONYLAMINO) ETHYL-1-OXO] PIPERIDINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION.
FR2710066B1 (en) * 1993-09-14 1995-10-20 Synthelabo 1- [2-amino-5- [1- (triphenylmethyl-1H-imidazol-4-yl] -1-oxopentyl] piperidine derivatives, their preparation and their use as synthesis intermediates.
FR2727410B1 (en) * 1994-11-25 1996-12-20 Synthelabo SULFONYL CHLORIDES, THEIR PREPARATION AND THEIR USE AS SYNTHESIS INTERMEDIATES
FR2728570B1 (en) * 1994-12-23 1997-04-11 Synthelabo 1-OXO-2- (PHENYLSULFONYLAMINO) PENTYLPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
DE19548797A1 (en) * 1995-12-27 1997-07-03 Thomae Gmbh Dr K New amino-imidazole substituted amino acid derivatives

Also Published As

Publication number Publication date
NO992436L (en) 1999-07-22
FR2756285B1 (en) 1998-12-18
WO1998022443A1 (en) 1998-05-28
NO992436D0 (en) 1999-05-20
IL129546A0 (en) 2000-02-29
EP0946517A1 (en) 1999-10-06
BR9713291A (en) 1999-10-26
AU5226498A (en) 1998-06-10
KR20000069063A (en) 2000-11-25
CN1238765A (en) 1999-12-15
CZ178299A3 (en) 1999-08-11
ZA9710515B (en) 1998-06-10
JP2001504128A (en) 2001-03-27
BG103414A (en) 2000-01-31
TR199901143T2 (en) 1999-08-23
EE9900201A (en) 1999-12-15
SK66799A3 (en) 2000-02-14
HUP9904599A2 (en) 2000-06-28
CO4910158A1 (en) 2000-04-24
CA2270478A1 (en) 1998-05-28
FR2756285A1 (en) 1998-05-29

Similar Documents

Publication Publication Date Title
AU572118B2 (en) 2-oxo-1,2,3,5-tetrahydroimidazo-(2,1-b) quinazolinyl derivatives
TW326447B (en) Substituted 2-phenylpyridines, intermediates and process for their preparation and application thereof
HUP0302367A2 (en) Aza and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors and pharmaceutical compositions containing them
AU528003B2 (en) N-substituted nitrogen-containing heterocyclic compounds
HUP0105108A2 (en) Amide compounds, process for their preparation and pharmaceutical compositions containing them
HUP0400837A2 (en) 2-phenyl-thiazole derivatives, their use and pharmaceutical compositions containing them
HUP0001796A2 (en) Dipeptide benzamidine as a kininogenase inhibitor and pharmaceutical compositions containing them
HUP9902410A2 (en) Amidino derivatives, preparation and use as thrombin inhibitors thereof, pharmaceutical compositions containing these compounds
ES8507112A1 (en) Dihydropyridine anti-ischaemic and antihypertensive agents.
DE69430373D1 (en) HYDROISOCHINOLINDERIVATE
DK0492369T3 (en) New tricyclic amino and nitro compounds with ACE inhibitory effect
HUP0301387A2 (en) Synthetic methods for preparation of aplidine and new antitumoral derivatives
MY132009A (en) Pharmaceutical compounds.
HUP9903590A2 (en) 3-azetidinylalkylpiperidines or -pyrrolidines as tachykinin antagonists
AR009627A1 (en) DERIVATIVES OF N- (IMIDAZOLYLBUTYL) BENZENOSULFONAMIDE ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS
MY100115A (en) Nitrogen containing heterocyclic compounds, and their production and use.
DK300890A (en) CONDENSED PYRAZOL-3-OXO PROPANNITRILLER DERIVATIVES AND PROCEDURES FOR PREPARING THEREOF
HUP9901434A2 (en) Substituted benzylamines and their use for the treatment of depression
IL76175A (en) N-substituted tricyclic oxindole carboxamides and pharmaceutical compositions containing them
ATE283261T1 (en) CYCLIC AMIDES AND IMIDES AND THEIR USE AS ALPHA-1D ADRENERGIC RECEPTOR ANTAGONISTS
ES8604928A1 (en) Dihydropyridine anti-ischaemic and antihypertensive agents.
ATE151423T1 (en) CARBOCYCLIC NUCLEOSIDE AGENTS USEFUL AS SELECTIVE INHIBITORS OF PROINFLAMMATORY CYTOKINES
ATE273284T1 (en) ARYLPHTALAZINE ANTAGONISTS OF EXITATONIC AMINO ACID RECEPTORS
MY103515A (en) Ergolinyl heterocycles
FR2769912B1 (en) NEW 3-OXO- (2H) -1,2,4 TRIAZINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS